Pharmacogenomic Effect/ADR for Tramadol (DBSNPE006646)

Identifier
DBSNPE006646
Drug
Tramadol (DB00193)
Interacting Gene/Enzyme
Cytochrome P450 2D6
Gene Name
CYP2D6
UniProt ID
P10635
Defining Change(s)
-1426C>TNot Available
-1235A>GNot Available
-1109C>TNot Available
-1000G>ANot Available
100C>TNot Available
310G>TNot Available
843T>GNot Available
1039C>TNot Available
1661G>CNot Available
2097A>GNot Available
2828delCNot Available
3384A>CNot Available
3582A>GNot Available
4180G>CNot Available
4401C>TNot Available
Allele Name
CYP2D6*100
Genotype(s)
Not Available
Type(s)
ADR Inferred Effect
Groups
Non-functional CYP2D6
Description
Poor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.
References
  1. UltramĀ® (tramadol hydrochloride) tablets[package insert]. Titusville, New Jersey: Janssen Pharmaceuticals, Inc.; 2016. [Link]